1. The FDA approved benralizumab, AstraZeneca’s drug for severe asthma, which will be known as Fasenra. It is expected to compete with GlaxoSmithKline’s Nucala and Teva’s Cinqair. (Reuters)

2. The Senate’s tax-reform bill includes a proposal that would repeal Obamacare’s individual mandate. (Axios)

3. Johnson & Johnson dropped its patent suit against Samsung Bioepis that aimed to block Remicade biosimilar Renflexis from coming to market. Remicade generates sales of about $5 billion per year. (Reuters)

4. President Trump’s pick to head the Department of Health and Human Services, former Eli Lilly executive Alex Azar, has blamed supply-chain inefficiencies as the primary reason for high drug prices. (Bloomberg)

 5. ICYMI: Under new hypertension guidelines proposed by the American Heart Association and the American College of Cardiology, nearly half of U.S. adults will be deemed to have high blood pressure. The guidelines move the threshold for high blood pressure to a reading of 130/80 and higher. (WSJ)